公开(公告)号：US20230037322A1

公开(公告)日：2023-02-09

申请号：US17849949

申请日：2022-06-27

申请人： Queen's University at Kingston

发明人： Rebecca Grange ,  John Allingham ,  Andrew Craig ,  P. Andrew Evans ,  Madhu Aeluri

IPC分类号： A61K31/45 ,  A61K31/221 ,  A61K31/25 ,  A61K31/341 ,  A61K31/397 ,  A61K31/4015 ,  A61K45/06 ,  A61K47/36 ,  C07C235/28 ,  C07C321/10 ,  C07D205/08 ,  C07D207/27 ,  C07D211/76 ,  C07D307/46

摘要： A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.

公开(公告)号：US11369594B2

公开(公告)日：2022-06-28

申请号：US16639207

申请日：2018-08-17

申请人： Queen's University at Kingston

发明人： Rebecca Grange ,  John Allingham ,  Andrew Craig ,  P. Andrew Evans ,  Madhu Aeluri

IPC分类号： A61K31/45 ,  A61K45/06 ,  A61K47/36 ,  A61K31/221 ,  A61K31/25 ,  A61K31/341 ,  A61K31/4015 ,  A61K31/397 ,  C07D211/76 ,  C07D207/27 ,  C07D205/08 ,  C07D307/46 ,  C07D321/10 ,  C07C235/28 ,  C07C321/10

摘要： A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.

公开(公告)号：US20200306233A1

公开(公告)日：2020-10-01

申请号：US16639207

申请日：2018-08-17

申请人： Queen's University at Kingston

发明人： Rebecca Grange ,  John Allingham ,  Andrew Craig ,  P. Andrew Evans ,  Madhu Aeluri

IPC分类号： A61K31/45 ,  A61K45/06 ,  A61K47/36 ,  A61K31/221 ,  A61K31/25 ,  A61K31/341 ,  A61K31/4015 ,  A61K31/397 ,  C07D211/76 ,  C07D207/27 ,  C07D205/08 ,  C07D307/46 ,  C07C321/10 ,  C07C235/28

摘要： A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.